title: Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
authors.affiliation: Clinical Division of Haematology and BMT Unit; "Antonio Perrino" Hospital , Brindisi , Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mele
authors.forename: Alessandro
authors.initials: A
authors.lastname: Spina
authors.forename: Gianluca
authors.initials: G
authors.lastname: Guaragna
authors.forename: Angela
authors.initials: A
authors.lastname: Giannotta
authors.forename: Angela
authors.initials: A
authors.lastname: Melpignano
authors.forename: Gianni
authors.initials: G
authors.lastname: Quarta
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D009588:Nitrogen Mustard Compounds; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000069461:Bendamustine Hydrochloride; D000077269:Lenalidomide